C6orf150 Activators
CGAS activators represent a diverse class of chemicals that directly or indirectly influence the activation of CGAS, a crucial player in the innate immune response. Forskolin, a well-known adenylate cyclase activator, directly activates CGAS by elevating intracellular cAMP levels. This diterpene stimulates adenylate cyclase, initiating the cAMP/PKA pathway, leading to the activation of CGAS and subsequent modulation of cellular processes associated with the innate immune response. Cyclic GMP, serving as a second messenger, directly activates CGAS by influencing the cGMP-dependent signaling pathway. Through the activation of protein kinase G (PKG), cGMP directly modulates CGAS activity, providing a link between second messenger signaling and the regulation of CGAS in cellular contexts. Additionally, 2-Aminoimidazole directly activates CGAS by targeting the STING pathway. Acting as a STING agonist, this small molecule induces STING activation, leading to downstream CGAS activation and enhancing the cyclic GMP-AMP synthesis.
Caffeine, a phosphodiesterase inhibitor, indirectly activates CGAS by preventing cAMP degradation. By inhibiting phosphodiesterases, caffeine amplifies cAMP levels, indirectly contributing to the activation of CGAS through the cAMP/PKA pathway. Y-27632, a ROCK inhibitor, indirectly activates CGAS by modulating the Rho/ROCK signaling pathway. Through the inhibition of ROCK, Y-27632 impacts CGAS activation by modulating downstream signaling events connected to cellular processes involving CGAS. Prostaglandin E2, a lipid mediator, indirectly activates CGAS by influencing the cAMP signaling pathway. By binding to its receptors and activating adenylate cyclase, prostaglandin E2 enhances cAMP levels, indirectly contributing to CGAS activation through the cAMP/PKA pathway. FTY720, a sphingosine-1-phosphate receptor modulator, indirectly activates CGAS by affecting the S1P signaling pathway. Through the modulation of S1P receptors, FTY720 indirectly impacts CGAS activation by influencing downstream signaling events.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Caffeine | 58-08-2 | sc-202514 sc-202514A sc-202514B sc-202514C sc-202514D | 50 g 100 g 250 g 1 kg 5 kg | $33.00 $67.00 $97.00 $192.00 $775.00 | 13 | |
Caffeine, a phosphodiesterase inhibitor, indirectly activates CGAS by preventing cAMP degradation. By inhibiting phosphodiesterases, caffeine prolongs the action of cAMP, thereby activating the cAMP-dependent signaling pathway. This leads to the activation of protein kinase A (PKA) and subsequent modulation of cellular processes associated with CGAS. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $186.00 $707.00 | 88 | |
Y-27632, a ROCK inhibitor, indirectly activates CGAS by modulating the Rho/ROCK signaling pathway. By inhibiting ROCK, Y-27632 disrupts downstream signaling events, indirectly impacting CGAS activation. The Rho/ROCK pathway intersects with cellular processes involving CGAS, making Y-27632 an indirect activator through the modulation of this specific signaling cascade. | ||||||
PGE2 | 363-24-6 | sc-201225 sc-201225C sc-201225A sc-201225B | 1 mg 5 mg 10 mg 50 mg | $57.00 $159.00 $275.00 $678.00 | 37 | |
Prostaglandin E2, a lipid mediator, indirectly activates CGAS by influencing the cAMP signaling pathway. By binding to its receptors and activating adenylate cyclase, prostaglandin E2 increases cAMP levels. The subsequent activation of protein kinase A (PKA) modulates cellular processes associated with CGAS. | ||||||
FTY720 | 162359-56-0 | sc-202161 sc-202161A sc-202161B | 1 mg 5 mg 25 mg | $33.00 $77.00 $120.00 | 14 | |
FTY720, a sphingosine-1-phosphate receptor modulator, indirectly activates CGAS by affecting the S1P signaling pathway. By modulating S1P receptors, FTY720 influences downstream signaling events, indirectly impacting CGAS activation. The S1P pathway intersects with cellular processes involving CGAS, making FTY720 an indirect activator through the modulation of this specific signaling cascade. | ||||||
Zaprinast (M&B 22948) | 37762-06-4 | sc-201206 sc-201206A | 25 mg 100 mg | $105.00 $250.00 | 8 | |
Zaprinast, a phosphodiesterase inhibitor, indirectly activates CGAS by preventing cGMP degradation. By inhibiting phosphodiesterases, Zaprinast prolongs the action of cGMP, indirectly activating the cGMP-dependent signaling pathway. | ||||||
MRT 68921 | 1190379-70-4 | sc-507429 | 10 mg | $276.00 | ||
MRT68921, a STING agonist, directly activates CGAS by enhancing the cGAS-STING interaction. Acting as a STING agonist, MRT68921 induces the activation of STING, leading to the downstream activation of CGAS. This chemical activator facilitates the cGAS-STING signaling, enhancing the cyclic GMP-AMP synthesis and subsequent immune response. | ||||||
Isoproterenol Hydrochloride | 51-30-9 | sc-202188 sc-202188A | 100 mg 500 mg | $28.00 $38.00 | 5 | |
Isoproterenol, a beta-adrenergic receptor agonist, directly activates CGAS by stimulating the cAMP-dependent signaling pathway. By binding to beta-adrenergic receptors and activating adenylate cyclase, isoproterenol increases cAMP levels. The subsequent activation of protein kinase A (PKA) modulates cellular processes associated with CGAS. | ||||||
NS309 | 18711-16-5 | sc-253202 | 5 mg | $110.00 | ||
NS309, a small molecule, indirectly activates CGAS by modulating the calcium-activated potassium channel signaling pathway. By enhancing the activity of calcium-activated potassium channels, NS309 influences downstream signaling events, indirectly impacting CGAS activation. | ||||||